Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel phage display based platform for exosome diversity characterization.
Maisano D, Mimmi S, Dattilo V, Marino F, Gentile M, Vecchio E, Fiume G, Nisticò N, Aloisio A, de Santo MP, Desiderio G, Musolino V, Nucera S, Sbrana F, Andò S, Ferrero S, Morandi A, Bertoni F, Quinto I, Iaccino E. Maisano D, et al. Among authors: gentile m. Nanoscale. 2022 Feb 24;14(8):2998-3003. doi: 10.1039/d1nr06804k. Nanoscale. 2022. PMID: 35141731
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations.
Maisano D, Iaccino E, D'Ambrosio A, Chiurazzi F, Dattilo V, Scalise M, Gentile M, Vecchio E, Nisticò N, Aloisio A, De Sensi E, Fiume G, Quinto I, Mimmi S. Maisano D, et al. Among authors: gentile m. Front Oncol. 2021 Jun 18;11:703254. doi: 10.3389/fonc.2021.703254. eCollection 2021. Front Oncol. 2021. PMID: 34222027 Free PMC article.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: gentile m. Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35608183 Free article.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Vincelli ID, Martino EA, Vigna E, Bruzzese A, Mendicino F, Botta C, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Falcone AP, Cangialosi C, Reddiconto G, Farina G, Barone M, Rizzello I, Iaccino E, Mimmi S, Curci P, Gamberi B, Musto P, De Stefano V, Musso M, Petrucci MT, Offidani M, Di Raimondo F, Boccadoro M, Cavo M, Neri A, Gentile M. Morabito F, et al. Among authors: gentile m. Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022. Front Oncol. 2022. PMID: 35924160 Free PMC article.
Elotuzumab in multiple myeloma.
Bruzzese A, Martino EA, Vigna E, Iaccino E, Mendicino F, Lucia E, Olivito V, Filippelli G, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: gentile m. Expert Opin Biol Ther. 2023 Jan;23(1):7-10. doi: 10.1080/14712598.2022.2145882. Epub 2022 Nov 14. Expert Opin Biol Ther. 2023. PMID: 36373842 No abstract available.
Isatuximab in multiple myeloma.
Martino EA, Bruzzese A, Iaccino E, Mendicino F, Mimmi S, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: gentile m. Expert Opin Biol Ther. 2023 Apr;23(4):315-318. doi: 10.1080/14712598.2023.2193289. Epub 2023 Mar 24. Expert Opin Biol Ther. 2023. PMID: 36943846 No abstract available.
Acalabrutinib in chronic lymphocytic leukemia.
Martino EA, Bruzzese A, Vigna E, Iaccino E, Mendicino F, Lucia E, Olivito V, Filippelli G, Neri A, Morabito F, Gentile M. Martino EA, et al. Among authors: gentile m. Expert Opin Pharmacother. 2023 Apr;24(5):545-549. doi: 10.1080/14656566.2023.2194486. Epub 2023 Mar 23. Expert Opin Pharmacother. 2023. PMID: 36943916 No abstract available.
Belantamab mafodotin in multiple myeloma.
Martino EA, Bruzzese A, Iaccino E, Labanca C, Mendicino F, Mimmi S, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: gentile m. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1043-1047. doi: 10.1080/14712598.2023.2218543. Epub 2023 May 27. Expert Opin Biol Ther. 2023. PMID: 37227998 No abstract available.
1,242 results